Videos

Hear strategies for how community-based oncology practices can combat the pervasive staff shortage by increasing efficiency and reducing staff burnout. Read More ›

Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib. Read More ›

Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting. Read More ›

Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study. Read More ›

Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer. Read More ›

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study. Read More ›

This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials. Read More ›

This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study. Read More ›

Dr Sanjay Juneja, medical oncologist and hematologist, and Chief of Oncology at Baton Rouge General Hospital–Mary Bird Perkins Cancer Center in Baton Rouge, LA, also known as “The Onc Doc,” is a well-known healthcare influencer. In the video above, Dr Juneja provides his perspectives on key efficacy and safety data from the EMERALD trial, the importance of testing for ESR1 mutations, and what the approval of ORSERDU (elacestrant) means for patients. Read More ›

Welcome to this virtual clinical utility study. It's being done to assess use of a novel biomarker in the treatment decision-making for immunotherapy-eligible first-line advanced stage non-small cell lung cancer patients. Read More ›